13 Nov 2012 08:40
Toumaz Limited
Issue of Equity
Toumaz Limited (AIM: TMZ, 'Toumaz', or 'the Company') announces that pursuant to the terms of the Acquisition Agreement (as defined in the Company's announcement of 3 July 2012), Toumaz has issued 833,613 new ordinary shares of 0.25p each ("Ordinary Shares") in settlement of deferred consideration due to a former employee of Frontier Silicon (Holdings) Limited ("Frontier") in respect of Frontier's acquisition by Toumaz.
The Company has applied for these 833,613 new Ordinary Shares ("New Shares") to be admitted to trading on AIM, which is expected to occur on 16 September 2012.
Following the admission to trading of the New Shares, Toumaz will have a total issued share capital of 1,134,806,210 Ordinary Shares.
The above figure of 1,134,806,210 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure and Transparency Rules.
For Further Enquiries:
Enquiries
Toumaz Limited Anthony Sethill, Chief Executive Officer
Peel Hunt LLP (Nominated Adviser and Broker) |
+44 (0)1235 438950
+44 (0)20 7418 8900 |
Richard Kauffer/Daniel Harris | |
College Hill | +44 (0)20 7457 2020 |
Adrian Duffield/Rozi Morris |
About Toumaz - (www.toumazltd.com)
Toumaz has established itself as a pioneer in low cost, ultra-low power wireless technologies for a wide range of markets including medical monitoring and internet connected consumer devices. The recent acquisition of Frontier brings operational scale and expertise together with a leadership position in digital and networked audio markets. The Group will combine its strong technology base with the commercial scale of Frontier to exploit two key wireless technology sectors:
·; Professional healthcare solutions
·; Consumer semiconductors in digital audio and sport & health markets
Targeting the professional healthcare market, Toumaz's ultra-low power sensor platform, Sensium™, is a leader in real-time wireless monitoring of the body's vital signs with the potential to transform medical monitoring and reduce the cost of healthcare. For healthcare professionals, this creates new opportunities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for personalised healthcare.
Toumaz plans to transfer its Sensium™ technology to the consumer sports and health market, where its advanced measurement algorithms and low energy solutions give it a competitive advantage.
Toumaz is also using its expertise to design devices for wireless connectivity and internet-connected consumer products. The strong relationship with Imagination Technologies gives Toumaz access to key technologies to exploit the high growth Network Audio market which is underpinned by the shift from physical media to cloud based music access and storage. The acquisition of Frontier has further enhanced the Group's technology portfolio in Network Audio and elevates Toumaz to a market leadership position in this and the digital radio markets. The Group now supplies multimedia/FM/DAB chips and modules to all major audio brands.
Toumaz is an AIM listed company (AIM: TMZ) with development centres in Oxford and Cambridge in the UK and in Hong Kong and in Shenzhen in the People's Republic of China.